GLP-1受体激动剂对2型糖尿病血糖控制、体重和血脂谱的比较有效性:系统综述与网络Meta分析
该系统综述与网络Meta分析纳入76项随机对照试验、15种GLP-1受体激动剂、39246例2型糖尿病成人患者,比较其血糖控制、体重和血脂谱的疗效与安全性。替尔泊肽在降低糖化血红蛋白和空腹血糖方面效果最佳,CagriSema减重效果最佳,司美格鲁肽可降低低密度脂蛋白和总胆固醇;研究同时提示需关注胃肠道不良事件,尤其高剂量给药时。
要点
- 替尔泊肽降低糖化血红蛋白和空腹血糖效果最佳,证据置信度高。
- CagriSema减重效果最佳(平均差-14.03 kg),其次为替尔泊肽。
- 司美格鲁肽可降低低密度脂蛋白和总胆固醇。
核心结论
- GLP-1受体激动剂对2型糖尿病成人患者有效。
- 与安慰剂相比,替尔泊肽是血糖控制最有效的GLP-1受体激动剂,可降低糖化血红蛋白和空腹血糖浓度。
- GLP-1受体激动剂也显著改善2型糖尿病患者的体重管理,其中CagriSema减重效果最佳。
- 结果提示需关注GLP-1受体激动剂的胃肠道不良事件安全性问题,尤其高剂量给药时。
研究设计与样本
- 系统综述与网络Meta分析,检索PubMed、Web of Science、Cochrane CENTRAL和Embase自建库至2023年8月19日。
- 纳入标准为成人2型糖尿病随机对照试验,接受GLP-1受体激动剂治疗并与安慰剂或任何GLP-1受体激动剂药物比较,随访至少12周。
- 排除交叉设计试验、无安慰剂组的非劣效性研究、使用已撤市药物的研究及非英文研究。
- 共纳入76项合格试验,涉及15种GLP-1受体激动剂药物和39246例参与者。
主要发现
- 所有15种GLP-1受体激动剂均有效降低糖化血红蛋白和空腹血糖浓度(均与安慰剂比较)。
- 替尔泊肽降低糖化血红蛋白幅度最大:平均差-2.10%(95%CI -2.47%至-1.74%),累积排序曲线下面积94.2%,证据置信度高。
- 替尔泊肽降低空腹血糖幅度最大:平均差-3.12 mmol/L(95%CI -3.59至-2.66),累积排序曲线下面积97.2%,证据置信度高。
- CagriSema(司美格鲁肽联合卡格列肽)减重幅度最大:平均差-14.03 kg(95%CI -17.05至-11.00),证据置信度高;替尔泊肽次之,平均差-8.47 kg(95%CI -9.68至-7.26),证据置信度高。
- 司美格鲁肽降低低密度脂蛋白浓度:平均差-0.16 mmol/L(95%CI -0.30至-0.02);降低总胆固醇浓度:平均差-0.48 mmol/L(95%CI -0.84至-0.11)。
关键数值与推荐
- 纳入标准:成人2型糖尿病、GLP-1受体激动剂治疗、与安慰剂或任何GLP-1受体激动剂药物比较、随访至少12周。
- 排除标准:交叉设计试验、无安慰剂组的非劣效性研究、使用已撤市药物、非英文研究。
- 系统综述注册号:PROSPERO CRD42022342845。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the comparative efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults with type 2 diabetes. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: PubMed, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), and Embase from database inception to 19 August 2023. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Eligible randomised controlled trials enrolled adults with type 2 diabetes who received GLP-1RA treatments and compared effects with placebo or any GLP-1RA drug, with a follow-up duration of at least 12 weeks. Trials with a crossover design, non-inferiority studies comparing GLP-1RA and other drug classes without a placebo group, using withdrawn drugs, and non-English studies were deemed ineligible. RESULTS: 76 eligible trials involving 15 GLP-1RA drugs and 39 246 participants were included in this network meta-analysis; all subsequent estimates refer to the comparison with placebo. All 15 GLP-1RAs effectively lowered haemoglobin A1c and fasting plasma glucose concentrations. Tirzepatide induced the largest reduction of haemoglobin A1c concentrations (mean difference -2.10% (95% confidence interval -2.47% to -1.74%), surface under the cumulative ranking curve 94.2%; high confidence of evidence), and fasting plasma glucose concentrations (-3.12 mmol/L (-3.59 to -2.66), 97.2%; high confidence), and proved the most effective GLP-1RA drug for glycaemic control. Furthermore, GLP-1RAs were shown to have strong benefits to weight management for patients with type 2 diabetes. CagriSema (semaglutide with cagrilintide) resulted in the highest weight loss (mean difference -14.03 kg (95% confidence interval -17.05 to -11.00); high confidence of evidence), followed by tirzepatide (-8.47 kg (-9.68 to -7.26); high confidence). Semaglutide was effective in lowering the concentration of low density lipoprotein (-0.16 mmol/L (-0.30 to -0.02)) and total cholesterol (-0.48 mmol/L (-0.84 to -0.11)). Moreover, this study also raises awareness of gastrointestinal adverse events induced by GLP-1RAs, and concerns about safety are especially warranted for high dose administration. CONCLUSIONS: GLP-1RAs are efficacious in treating adults with type 2 diabetes. Compared with the placebo, tirzepatide was the most effective GLP-1RA drug for glycaemic control by reducing haemoglobin A1c and fasting plasma glucose concentrations. GLP-1RAs also significantly improved weight management for type 2 diabetes, with CagriSema performing the best for weight loss. The results prompt safety concerns for GLP-1RAs, especially with high dose administration, regarding gastrointestinal adverse events. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022342845.
引用
- Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024. PMID: 38286487. doi:10.1136/bmj-2023-076410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。